Home » Newsletters » BioWorld Science

BioWorld Science

April 4, 2003

View Archived Issues

Topical thalidomide safe and well tolerated

Wyeth exercises option for Oxford BioMedica's anticancer antibody

ICN to supply ribavirin for investigational use in treating SARS

FDA approves GSK's sNDA for Valtrex for suppression of genital herpes in HIV patients

Oxymorphone ER and IR in acute and chronic pain

Sepracor's Estorra moves into formal review

Topline results for alvimopan phase III study

Pleiotropic cardiovascular effects of pitavastatin

Daiichi and Pfizer to codevelop extended-spectrum quinolone

Achillion and U. of Maryland discover novel HIV target

Analgesic effects of lidocaine 5% patches

Tacrolimus ointment in atopic dermatitis

Results reported for azelaic acid 15% gel in rosacea

Patrin enters phase II trial in metastatic melanoma

Epimmune discovers candidates for HPV vaccine under Genencor collaboration

Galen enters agreements for psoriasis treatments

Phase III program under way for Seboride

Preclinical evaluation of rhATIII for treatment of acute lung injury

Phase II repifermin trial demonstrates efficacy in cancer therapy-induced mucositis

Orally available ACAT inhibitor described in Kowa patent

Novel antidiabetic PPAR modulators discovered by Pfizer researchers

Pfizer researchers prepare and test new MMP-13 inhibitors

MIP-1alpha modulators and their use in arthritis, asthma, COPD and multiple sclerosis

New synthetic gangliosides with utility in glioma and neurological disorders

BMS identifies new factor VIIa inhibitors

PTK-787/ZK-222584 enters phase III for metastatic colorectal cancer

Spheramine shows sustained benefit over two years in Parkinson's disease

N,N-Disubstituted phenylalanines with potent, selective activity against HCV NS5B polymerase

Water-soluble semisynthetic nocathiacin derivatives developed at BMS

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...